Disclaimer

The information on this website is presented as a service for our clients and Internet users and is not intended to be legal advice, nor should you consider it as such. Although we welcome your inquiries, please keep in mind that merely contacting us will not establish an attorney-client relationship between us. Consequently, you should not convey any confidential information to us until a formal attorney-client relationship has been established. Please remember that electronic correspondence on the internet is not secure and that you should not include sensitive or confidential information in messages. With that in mind, we look forward to hearing from you.

 Skip to Content

Carlton Fields Wins Appellate Victory in Biotech Investor Dispute
February 25, 2019
Carlton Fields attorneys secured the dismissal of $13 million in claims, including breach of contract, filed by an investor in the biotech company Islet Sciences, Inc. In a February 25, 2019 opinion, the U.S. Court of Appeals for the Second Circuit affirmed the decision of the trial court in the Southern District of New York that had earlier tossed the lawsuit. Plaintiff Richard Schoninger claimed to have invested $1 million in Islet Sciences in exchange for an oral promise by Islet Sciences’ officers to merge their separately owned company, Brighthaven Ventures, LLC, (d/b/a BHV Pharma) into Islet Sciences. Brighthaven owns the development rights for the Type 2 diabetes drug Remogliflozin-Etabonate, which Islet Sciences wished to acquire. The merger agreement was mutually terminated by the parties and never occurred.
 
Carlton Fields Shareholders Michael D. Margulies and Robert Novack won summary judgment on behalf of their clients. The Court of Appeals affirmed the District Court’s decision that no oral agreement was ever reached.
Featuring
Image: Michael D. Margulies
Michael D. Margulies
Image: Robert Novack
Robert Novack
Related Practices
Appellate & Trial Support Litigation and Trials Pharmaceuticals and Medical Devices